We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Researchers Pinpoint Binding Site for Clostridium difficile Binary Toxin

By LabMedica International staff writers
Posted on 21 Jun 2015
Print article
Image: Bacterial toxins usually exert their full deadly effect in the host cell\'s interior. The toxins overcome the cell membrane by binding to a surface receptor, which conveys them into the cell\'s interior (Photo courtesy of Dr. Panagiotis Papatheodorou, University of Freiburg).
Image: Bacterial toxins usually exert their full deadly effect in the host cell\'s interior. The toxins overcome the cell membrane by binding to a surface receptor, which conveys them into the cell\'s interior (Photo courtesy of Dr. Panagiotis Papatheodorou, University of Freiburg).
A team of molecular microbiologists has located the site where the bacterium Clostridium difficile's binary toxin binds to intestinal cells' LSR (lipolysis-stimulated lipoprotein receptor) protein and triggers a mechanism that results in the invasion of the host cells by the bacteria.

Clostridium difficile is a serious intestinal pathogen that can cause severe diarrhea and life-threatening intestinal infections especially after long-term treatment with antibiotics. The bacteria produce the binary, actin ADP-ribosylating toxin CDT (Clostridium difficile transferase). While CDT can lead to death of the host cells through collapse of the actin cytoskeleton, low doses of CDT result in the formation of microtubule-based protrusions on the cell surface that increase the adherence and colonization of C. difficile.

Investigators at the University of Freiburg (Germany) examined how CDT binds to its host cell LSR. They reported in the April 16, 2015, online edition of the Journal of Biological Chemistry that CDT interacted with the extracellular, Ig-like domain of LSR with an affinity in the nanomolar range. They identified LSR splice variants in the colon carcinoma cell line HCT116 and disrupted the LSR gene in these cells by applying CRISPR-Cas9 technology.

CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. CRISPRs are found in approximately 40% of sequenced bacteria genomes and 90% of sequenced archaea. CRISPRs are often associated with cas genes that code for proteins related to CRISPRs. The CRISPR/Cas complex comprises a prokaryotic immune system that confers resistance to foreign genetic elements such as plasmids and phages and provides a form of acquired immunity. Since 2013, the CRISPR/Cas system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 protein and appropriate guide RNAs into a cell, the organism's genome can be cut at any desired location.

LSR segments created by the CRISPR/Cas technique were expressed ectopically in cells lacking the LSR gene. Results of these experiments showed that intracellular parts of LSR were not essential for plasma membrane targeting of the receptor and cellular uptake of CDT. Furthermore, by generating a series of N- and C-terminal truncations of the binding component of CDT (CDTb), they found that amino acids 757 to 866 of CDTb were sufficient for binding to LSR.

"In the future, it should be possible to block these areas in the toxin and receptor in order to prevent the toxin from entering the host cell," said senior author Dr. Panagiotis Papatheodorou, professor of biology at the University of Freiburg.

Related Links:

University of Freiburg


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.